Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Actavis mulls Biopartners' stake to enter biogenerics

This article was originally published in Scrip

Executive Summary

Actavis of Iceland is planning to acquire the 51% stake in Biopartners, the Swiss biogenerics company, currently owned by Poland's largest biotech company, Bioton. Financial terms of the deal have yet to be agreed and will take into account the $78 million that Bioton paid for Biopartners in 2007, the cost of goods associated with the portfolio as well as its commercialisation prospects.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts